Biotech | December 13, 2021
Zydus to begin Phase II (a) clinical trial of ZYIL1 in Australia
It is a novel oral NLRP3 inflammasome inhibitor
It is a novel oral NLRP3 inflammasome inhibitor
Under this scheme, the company will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products
The tablets are indicated for the treatment of pulmonary arterial hypertension
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
_256_384.jpg)
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
He has more than 285 publications with 7,600 citations, 80 students have already been awarded Ph. D. degree under his able guidance and 20 postdoctoral associates have worked in his group
Serum has a capacity of 250-275 million whereas Bharat Biotech has a capacity of 50-60 million
The product will be commercialized from Unichem's Ghaziabad plant
This further adds to Biocon’s portfolio of vertically integrated complex drug products
The offline store launch will complement the E-commerce website in building a rich consumer shopping experience
Subscribe To Our Newsletter & Stay Updated
